PDCD1LG2 and neoplasm: In myelodysplastic syndromes (MDS) and AML patient samples, PD-L1 was detectable (> 2% PD-L1+ cells) in 100% of patients with common expression on non-tumor hematopoietic cells, while PD-L2 expression was largely absent [23].